Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: A retrospective study

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 3, 2009, Pages 667-669

  Sarfo, Fred S ^a   Bibby, David F ^b   Schwab, Uli ^a   Appiah, Lambert T ^a   Clark, Duncan A ^b   Collini, Paul ^a   Phillips, Richard ^a   Green, Ingrid ^b   Dittmar, Matthias T ^c   Chadwick, David R ^d  

^a KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Ghana; HIV; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS NEVIRAPINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DOSE RESPONSE; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; VIRUS LOAD; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GHANA; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 69049096138     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp216     Document Type: Letter

References (6)

1. Sagoe K, Mingle J, Affram R et al. Virological characterization of dual HIV-1/HIV-2 seropositivity and infections in Southern Ghana. Ghana Med J 2008; 42: 16-21.
2. Schim van der Loeff MF, Jaffar S, Aveika AA et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002; 16: 1775-83.
3. Collini P, Schwab U, Sarfo S et al. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort. Clin Infect Dis 2009; 48: 988-91.
4. Ndour CT, Batista G, Manga NM et al. Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: Preliminary study. Med Mal Infect 2006; 36: 111-4.
5. Ruelle J, Roman F, Vandenbroucke AT et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis 2008; 8: 21.
6. Landman R, Damond F, Gerbe J et al. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS 2009; 23: 426-8.